RANKL inhibition: a new target of treating diabetes mellitus?

Accumulating evidence demonstrates the link between glucose and bone metabolism. The receptor activator of nuclear factor-kB ligand (RANKL)/the receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) axis is an essential signaling axis maintaining the balance between bone resorption and bone format...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Baodi, Yu, Jie, Zhang, Huabing, Li, Yuxiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201162/
https://www.ncbi.nlm.nih.gov/pubmed/37223831
http://dx.doi.org/10.1177/20420188231170754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201162/
https://www.ncbi.nlm.nih.gov/pubmed/37223831
http://dx.doi.org/10.1177/20420188231170754

Ejemplares similares